There’s a buzz around cell & gene therapy (CGT). Attribute this to the promise these therapies hold for patients with rare and often deadly inherited diseases; the scientific intrigue of gene editing; and the potential business opportunities circling these revolutionary therapies. But, what’s next for CGT?
Signals Analytics, with its leading cloud-based data platform – Signals Playbook™ – has explored the data and created an in-depth white paper that breaks down the CGT ecosystem with smart charts and expert commentary. Download the white paper